Products Categories
CAS No.: | 2746-81-8 |
---|---|
Name: | fluphenazine O-enantate |
Molecular Structure: | |
Formula: | C29H38 F3 N3 O2 S |
Molecular Weight: | 549.701 |
Synonyms: | Heptanoicacid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester (7CI,8CI); 1-Piperazineethanol,4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-, heptanoate (ester) (8CI);4-[3-(2-Trifluoromethyl-10-phenothiazinyl)propyl]-1-piperazineethanolenanthate; Fluphenazine enanthate; Moditen enanthate; Prolixin enanthate; SQ16,114; SQ 16144 |
Density: | 1.181g/cm3 |
Melting Point: | 184.5°C |
Boiling Point: | 629.4°Cat760mmHg |
Flash Point: | 334.4°C |
Safety: | Poison by intravenous, intramuscular, intraperitoneal, and subcutaneous routes. Human systemic effects by subcutaneous route: muscle weakness; by intramuscular route: musculo-skeletal changes. When heated to decomposition it emits very toxic fumes of F−, SOx, and NOx. |
PSA: | 61.32000 |
LogP: | 6.77020 |
What can I do for you?
Get Best Price
IUPAC Name: 2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl heptanoate
Synonyms of Prolixin enanthate (CAS NO.2746-81-8): 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl heptanoate ; 4-(3-(2-Trifluoromethyl-10-phenothiazinyl)propyl)-1-piperazineethanol enanthate ; Eutimox ; Fluphenazine enantate ; Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
CAS NO: 2746-81-8
Molecular Formula: C29H38F3N3O2S
Molecular Weight : 549.6911
Molecular Structure:
EINECS: 220-385-0
H bond acceptors: 5
H bond donors: 0
Freely Rotating Bonds: 13
Polar Surface Area: 61.32 Å2
Index of Refraction: 1.544
Molar Refractivity: 146.97 cm3
Molar Volume: 465.4 cm3
Surface Tension: 40.6 dyne/cm
Density: 1.181 g/cm3
Flash Point: 334.4 °C
Enthalpy of Vaporization: 93.11 kJ/mol
Boiling Point: 629.4 °C at 760 mmHg
Vapour Pressure: 9.41E-16 mmHg at 25°C
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
human | TDLo | intramuscular | 1633ug/kg (1.633mg/kg) | MUSCULOSKELETAL: OTHER CHANGES | British Medical Journal. Vol. 2, Pg. 1071, 1966. |
human | TDLo | subcutaneous | 357ug/kg (0.357mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS | American Journal of Psychiatry. Vol. 119, Pg. 779, 1963. |
mouse | LD50 | intramuscular | 17200ug/kg (17.2mg/kg) | Drugs in Japan Vol. 6, Pg. 701, 1982. | |
mouse | LD50 | intraperitoneal | 300mg/kg (300mg/kg) | Drugs in Japan Vol. 6, Pg. 701, 1982. | |
mouse | LD50 | intravenous | 56mg/kg (56mg/kg) | U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#03337, | |
mouse | LD50 | oral | 41300ug/kg (41.3mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
mouse | LD50 | subcutaneous | 50mg/kg (50mg/kg) | Drugs in Japan Vol. 6, Pg. 701, 1982. | |
rat | LD50 | intraperitoneal | 230mg/kg (230mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
rat | LD50 | oral | 230mg/kg (230mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
rat | LD50 | subcutaneous | 475mg/kg (475mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969. | |
women | TDLo | intramuscular | 250ug/kg (0.25mg/kg) | BRAIN AND COVERINGS: CHANGES IN SURFACE EEG BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: COMA | Italian Journal of Neurological Sciences. Vol. 1, Pg. 193, 1980. |
Poison by intravenous, intramuscular, intraperitoneal, and subcutaneous routes. Human systemic effects by subcutaneous route: muscle weakness; by intramuscular route: musculo-skeletal changes. When Prolixin enanthate (CAS NO.2746-81-8) is heated to decomposition, it emits very toxic fumes of F−, SOx, and NOx.
RIDADR: 3249
HazardClass: 6.1(b)
PackingGroup: III